GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2012

BerGenBio Raises $8.8M to Advance Axl Kinase Inhibitor Drug Into Clinical Trials

  • Norwegian-owned BerGenBio completed an $8.8 million Series A financing round, primarily to take lead cancer compound BGB324 into clinical trials and to develop a companion diagnostic.

    BGB324, the oncology biopharma’s first-in-class Axl kinase inhibitor drug, is the first of a pipeline of oncology therapeutics planned for clinical development through to Phase II, in partnership with industry leaders.

    BGB324 inhibited tumor development in preclinical acute myelogenous leukemia models, according to data presented at the annual American Society for Hematology conference. BerGenBio also presented data showing that inhibition of Axl blocks the epithelial-mesenchymal transition in cancer cells and has potential to delay or prevent metastasis, overcome and even reverse acquired resistance to chemotherapy and possibly prevent cancer recurrence.

    Lead investors are the Norwegian seed capital fund Sarsia Seed and Investinor, a Norwegian-government-owned venture investment company.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »